HMGN logo

Hemagen Diagnostics OTCPK:HMGN Stock Report

Last Price

US$0.000001

Market Cap

US$15.0

7D

0%

1Y

-99.0%

Updated

03 Mar, 2024

Data

Company Financials

Hemagen Diagnostics, Inc.

OTCPK:HMGN Stock Report

Market Cap: US$15.0

HMGN Stock Overview

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide.

HMGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Hemagen Diagnostics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hemagen Diagnostics
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.0001
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Change-99.00%
3 Year Change-100.00%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

HMGNUS Medical EquipmentUS Market
7D0%-0.2%1.3%
1Y-99.0%10.6%29.8%

Return vs Industry: HMGN underperformed the US Medical Equipment industry which returned 9.9% over the past year.

Return vs Market: HMGN underperformed the US Market which returned 24.4% over the past year.

Price Volatility

Is HMGN's price volatile compared to industry and market?
HMGN volatility
HMGN Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: HMGN has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HMGN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985n/aWilliam Haleshttps://www.hemagen.com

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines.

Hemagen Diagnostics, Inc. Fundamentals Summary

How do Hemagen Diagnostics's earnings and revenue compare to its market cap?
HMGN fundamental statistics
Market capUS$15.00
Earnings (TTM)-US$907.31k
Revenue (TTM)US$4.04m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HMGN income statement (TTM)
RevenueUS$4.04m
Cost of RevenueUS$2.43m
Gross ProfitUS$1.61m
Other ExpensesUS$2.52m
Earnings-US$907.31k

Last Reported Earnings

Sep 30, 2012

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did HMGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.